This technology is an in vitro platform for generating pure alveolar type II cells from lung organoids for lung disease modeling and cell replacement therapy.
Current methods to generate lung progenitors and derived lineages (e.g., alveolar cells) in vitro suffer from low efficiency. Several methods have been developed to overcome this issue, but they require sequential sorting or purification steps. Other methods require mesenchymal stems for cell propagation or suffer from low stability over multiple growth stages.
This platform generates pure alveolar type II cells from ‘lung bud organoids’ without requiring purification steps. It does so by dissociating lung organoids that do not require isolation steps for generation into single cells. Hematopoietic stem cells (hPSCs) are maintained in the presence of feeders, and definitive endoderm is produced in-house to maintain future lung cell potential. Cells can be expanded by ~10-fold every two weeks.
This technology has been tested with lung bud organoids and cultured for up to 12 weeks.
Hans-Willem Snoeck, M.D., Ph.D.
Patent Pending
IR CU22319, CU22318, CU17197
Licensing Contact: Joan Martinez
